Vicore Pharma Holding AB (6Y4) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Buloxibutid | Idiopathic Pulmonary Fibrosis (Ipf) | Phase II | Recruiting | A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. | Sep 06, 2024 | ― |
| Drug Drug Interaction | Drug Interaction | Phase I | Completed | A Trial to Evaluate the Impact of C21 on the Exposure of 4 Substrates in Healthy Volunteers | Mar 24, 2023 | ― |
| C21 | Type2diabetes, Endothelial Dysfunction | Phase I | Completed | A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 Diabetes | Mar 13, 2023 | ― |
| C106 Solution | Safety Issues, Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension, Tolerance | Phase I | Completed | First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects | Jun 07, 2022 | ― |
| C21, Sodium Nitroprusside | Study Vasodilatory Effects Of C21 | Phase I | Completed | Effect of C21 on Forearm Blood Flow | Mar 03, 2022 | ― |
| C21 | Idiopathic Pulmonary Fibrosis | Phase II | Completed | Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF | Aug 26, 2020 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Buloxibutid | Phase II | Idiopathic Pulmonary Fibrosis (Ipf) | Recruiting | A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. | Sep 06, 2024 | ― |
| Drug Drug Interaction | Phase I | Drug Interaction | Completed | A Trial to Evaluate the Impact of C21 on the Exposure of 4 Substrates in Healthy Volunteers | Mar 24, 2023 | ― |
| C21 | Phase I | Type2diabetes, Endothelial Dysfunction | Completed | A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 Diabetes | Mar 13, 2023 | ― |
| C106 Solution | Phase I | Safety Issues, Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension, Tolerance | Completed | First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects | Jun 07, 2022 | ― |
| C21, Sodium Nitroprusside | Phase I | Study Vasodilatory Effects Of C21 | Completed | Effect of C21 on Forearm Blood Flow | Mar 03, 2022 | ― |
| C21 | Phase II | Idiopathic Pulmonary Fibrosis | Completed | Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF | Aug 26, 2020 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Vicore Pharma Holding AB (DE:6Y4) have in its pipeline
Vicore Pharma Holding AB DE:6Y4 is currently developing the following drugs: Buloxibutid, Drug Drug Interaction, C21, C106 Solution, C21, Sodium Nitroprusside. These drug candidates are in various stages of clinical development as the company works toward FDA approval.